Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
Por:
Cortes, J, Ciruelos, E, Perez-Garcia, J, Albanell, J, Garcia-Estevez, L, Ruiz-Borrego, M, Espinosa, R, Gallegos, I, Gonzalez, S, Alvarez, I and Llombart, A
Publicada:
1 feb 2020
Resumen:
The use of adjuvant pertuzumab in HER2-positive early-stage breast cancer has recently been approved by the EMA on the basis of data from the APHINITY trial. Accordingly, we have produced this opinion article with the aim of putting the study data in perspective against other add-on therapeutic strategies, to clarify methodological or statistical doubts about the study, and to define the population of high-risk patients with hormone receptor-negative breast cancer that we agree, in general, should be treated. With this approval, physicians must be well prepared to place the APHINITY study data in context. It is now up to each country to ratify the EMA-approved indications and to agree on reimbursement, and doctors must optimize their use based on knowledge and discussion with patients.
Filiaciones:
Cortes, J:
IOB Inst Oncol, Quironsalud Grp, Madrid, Spain
IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain
VHIO, Barcelona, Spain
Ciruelos, E:
Hosp Univ 12 Octubre, Madrid, Spain
HM Ctr Integral Oncol Clara Campal CIOCC, Madrid, Spain
SOLTI Breast Canc Res Cooperat Grp, Barcelona, Spain
Perez-Garcia, J:
IOB Inst Oncol, Quironsalud Grp, Madrid, Spain
IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain
Med Scientia Innovat Res MedSIR, Barcelona, Spain
Albanell, J:
Hosp del Mar, Barcelona, Spain
Garcia-Estevez, L:
MD Anderson Canc Ctr, Madrid, Spain
Ruiz-Borrego, M:
Hosp Virgen Rocio, Seville, Spain
Espinosa, R:
Hosp Gen La Mancha Ctr, Ciudad Real, Spain
Gallegos, I:
Hosp Gen Segovia, Segovia, Spain
Gonzalez, S:
Hosp Univ San Pedro Alcantara, Caceres, Spain
Alvarez, I:
Hosp Univ Donostia, San Sebastian, Spain
:
Hosp Arnau Vilanova, Valencia, Spain
Univ Catolica Valencia, Valencia, Spain
|